Upstream Bio, Inc. (NASDAQ:UPB) Stock Rated “Hold” by Wall Street Analysts

Upstream Bio, Inc. (NASDAQ:UPB) has been assigned an average recommendation of “Hold” from the seven ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $29.67.

UPB has been the subject of a number of recent analyst reports. Wall Street Zen lowered shares of Upstream Bio from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Truist Financial cut their price objective on shares of Upstream Bio to $25.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Weiss Ratings raised shares of Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 17th. HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of Upstream Bio in a research report on Wednesday, September 2nd. Finally, JPMorgan Chase & Co. lifted their target price on Upstream Bio from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Friday, August 14th.

Upstream Bio Stock Performance

UPB stock opened at $3.23 on Friday. The firm has a market cap of $176.91 million, a P/E ratio of -1.11 and a beta of 1.60. Upstream Bio has a 1 year low of $2.68 and a 1 year high of $33.68. The stock has a 50-day simple moving average of $4.57 and a 200-day simple moving average of $8.80.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.01. The firm had revenue of $0.77 million for the quarter, compared to analyst estimates of $0.56 million. Upstream Bio had a negative return on equity of 48.40% and a negative net margin of 4,955.67%. On average, equities research analysts predict that Upstream Bio will post -2.84 EPS for the current year.

Institutional Trading of Upstream Bio

A number of hedge funds have recently made changes to their positions in UPB. BlackRock Inc. acquired a new position in shares of Upstream Bio during the second quarter valued at $25,973,000. Parkman Healthcare Partners LLC bought a new position in shares of Upstream Bio during the second quarter worth about $6,472,000. SEB Asset Management AB acquired a new stake in shares of Upstream Bio in the 1st quarter worth about $7,906,000. Hsbc Holdings PLC acquired a new stake in shares of Upstream Bio in the 1st quarter worth about $5,763,000. Finally, Walleye Capital LLC bought a new stake in Upstream Bio in the 2nd quarter valued at about $3,450,000.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on developing therapies for inflammatory and immune-mediated diseases. The company’s research is centered on targeting pathways involved in type 2 inflammation, which contributes to conditions affecting the respiratory system and other tissues.

Its lead product candidate is verekitug, an investigational, long-acting monoclonal antibody designed to block thymic stromal lymphopoietin (TSLP), an epithelial cytokine that plays a role in initiating and maintaining allergic and inflammatory responses.